When was IDRx founded?

IDRx was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is IDRx located?

IDRx is headquartered in Plymouth, United States.

How many employees does IDRx have?

As of Mar 31, 2026, the latest employee count at IDRx is 14.

Is IDRx a funded company?

IDRx is a funded company, having raised a total of $242M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Aug 02, 2022.

How much is IDRx worth?

The last known valuation of IDRx was $***** as of Jan 08, 2025.

When was the latest funding round of IDRx?

IDRx's latest funding was a $***** Series B round on Aug 07, 2024, with participation from 9 investors.

Where does IDRx rank among its competitors?

IDRx ranks 1st amongst 7 active competitors, only 1 of which is funded., of which only Shgsmed.com is funded and secured an undisclosed amount in Nov, 2024.

Who are the top competitors of IDRx?

IDRx's top competitors include Draconis Pharma, Intima Bioscience and Checkmate Therapeutics. Among them, Shgsmed.com secured the most recent funding round in November, 2024.

IDRx - 2026 Company Profile, Team, Funding & Competitors

Q: Is IDRx an acquired company?

IDRx got acquired by GSK on Jan 08, 2025.

Company Details

Developer of precision combination therapies for cancer. It offers IDRX-42 and IDRX-73 small molecule tyrosine kinase inhibitors to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumors.

Website: idrx.com
Email ID: *****@idrx.com

Key Metrics

Founded Year

2022

Location

Plymouth, United States

Stage

Acquired

Total Funding

$242M in 2 rounds

Latest Funding Round

Series B, Aug 07, 2024, $*****

Last Known Valuation

$***** as on Jan 08, 2025

Investors

Andreessen Horowitz & 9 more

Ranked

1^st among 7 active competitors

Employee Count

14 as on Mar 31, 2026

Similar Companies

Draconis Pharma & 7 more

Exit Details

Acquired by GSK (Jan 08, 2025)

View IDRx's full profile

IDRx got acquired by GSK on Jan 08, 2025 at an acquisition amount of $1.25B. It was facilitated by Leerink Partners.

Click here to take a look at IDRx's acquisition in detail

IDRx has raised a total funding of $242M over 2 rounds. Its first funding round was on Aug 02, 2022. Its latest funding round was a Series B round on Aug 07, 2024 for $*****. 9 investors participated in its latest round. IDRx has 10 institutional investors.

Here is the list of recent funding rounds of IDRx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 07, 2024	4166788	Series B	7115206	3210965	7173878	5386276
Aug 02, 2022	3701616	Series A	9034740	2700426	Andreessen Horowitz & 3 more	2990419

Access funding benchmarks and valuations. Sign up today!

View details of IDRx's funding rounds and investors

The founders of IDRx are Nicholas Lydon and Alexis Borisy.

Here are the details of IDRx's key team members:

Nicholas Lydon: Co-Founder of IDRx and founder of 1 other company.
Alexis Borisy: Co-Founder of IDRx.
Contact Info: 1 email address

View details of IDRx's Founder profiles and Board Members

IDRx's employee count trend

IDRx has 14 employees as of Mar 26. Here is IDRx's employee count trend over the years:

Uncover IDRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of IDRx include Draconis Pharma, Intima Bioscience and Checkmate Therapeutics. Here is the list of Top 10 competitors of IDRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	IDRx 2022, Plymouth (United States), Acquired	Developer of precision combination therapies for cancer	$242M	RA Capital Management, Commodore Capital & 8 others	63/100
2nd	Draconis Pharma 2011, Barcelona (Spain), Funding Raised	Developer of therapeutic solutions for the treatment of therapies for the treatment of cancer, pain, & other diseases	-	Atiquity, TIBIDABO VENTURES	30/100
3rd	Intima Bioscience 2014, New York City (United States), Funding Raised	Developer of therapeutics to treat gastrointestinal cancer using CRISPR gene-editing technology	-	Morningside	27/100
4th	Checkmate Therapeutics 2019, Seoul (South Korea), Unfunded	Developer of therapeutics for cancer and neurological disorders	-	-	24/100
5th	Ganymed 2001, Mainz (Germany), Funding Raised	Developer of antibodies to treat cancer	-	Salvia	18/100
6th	Velcade 2002, Unfunded	Provider of pharmaceutical products focused on thoracic, gastrointestinal, and hematologic cancers	-	-	16/100
7th	Shgsmed.com 2019, Seed	Developer of drugs for cancer treatment	-	-	16/100
8th	Kupffer Biotherapeutics 2019, Burlingame (United States), Deadpooled	Developer of anticancer therapy for gastrointestinal cancer	-	-	15/100
9th	TLR Therapeutics 2022, Wilmington (United States), Deadpooled	Developer of therapeutics for the treatment of myelodysplastic syndrome and gastric cancer	-	-	15/100